臺灣博碩士論文加值系統

Pfizer Incorporated is the largest multinational Pharmaceutical Company. Its headquarters is located in United States of America, and they have with 530 subsidiaries in 150 countries, including Taiwan. Pfizer have been the leading Pharmaceutical Company with the most Revenues for many years, and in term of revenue they have earned more than what other Pharmaceutical Companies could have earned. However ever since Pfizer suffered decline in Revenue in 2012, Novartis has taken over its leading position. Despite of the recent downturn, it still does not change the fact that Pfizer Inc. has already achieved more them US$ 1 billion Exponential Return since years ago. Therefore, Pfizer Inc. is one of the Blueprints for the High-Growth Companies.
This study case is conducted to analyze they relations between the Seven Essentials to Achieve Exponential Growth by David G. Thomson and the success of Pfizer Inc. and Pfizer Ltd. Taiwan. With the Value Prepositions as the foundation of essentials, implementation of Market Segments, identification of real Marquee Customers, establishment of powerful Strategic Alliances, successful achievement of Exponential Returns, and solid Leadership formation within the Management Team and the Board Members, Pfizer Inc. are able to attain High-Growth, maintain performance and become one of the Giants.

ABSTRACT i
ACKNOWLEDGEMENT ii
TABLE OF CONTENTS iii
LIST OF TABLES v
LIST OF FIGURES vi
CHAPTER 1: INTRODUCTION 1
1.1 Research Background and Motivation 1
1.2 Research Objectives 2
1.3 Research Content and Flowchart 2
1.4 Research Limitations 3
CHAPTER 2: LITERATURE REVIEW 5
2.1 High-Growth Companies 5
2.2 Seven Essentials to Achieve Exponential Growth 6
2.2.1 Value Proposition 7
2.2.2 Market Segments 9
2.2.3 Marquee Customers 10
2.2.4 Strategic Alliances 11
2.2.5 Exponential Returns 13
2.2.6 Leadership and Management Team 15
2.2.7 Board Members 18
CHAPTER 3: RESEARCH METHODOLOGY 20
3.1 Research Method 20
3.2 Data Collection 20
3.2.1 Primary Data 20
3.2.2 Secondary Data 22
CHAPTER 4: INDUSTRY ANALYSIS 23
4.1 Pharmaceutical Industry 23
4.1.1 Market Share 24
4.1.2 Research and Development Intensity 25
4.1.3 Changing Environment 29
4.2 Pfizer Incorporated 31
4.2.1 Our Path Forward 33
4.2.1.1 Our Purpose 33
4.2.1.2 Our Mission 33
4.2.1.3 Our Commitments 34
4.2.1.4 Our Strategies 34
4.2.1.5 Our Values 35
4.2.2 Market Share 35
4.2.3 Core Competences 35
4.2.4 Acquiring, Integrating and Restructuring 41
4.2.4.1 Acquisitions 41
4.2.4.2 Alliances 42
4.2.5 SWOT Analysis 43
4.2.5.1 Strengths 43
4.2.5.2 Weaknesses 44
4.2.5.3 Opportunities 45
4.2.5.4 Treats 45
4.3 Pfizer Limited Taiwan 46
4.3.1 SWOT Analysis 47
4.3.1.1 Strengths 47
4.3.1.2 Weaknesses 48
4.3.1.3 Opportunities 48
4.3.1.4 Threats 48
CHAPTER 5: CASE STUDY ANALYSIS 49
5.1. Pfizer Inc. Value Preposition 49
5.2 Pfizer Ltd. Taiwan Market Segments 52
5.2.1 Market Share 52
5.2.2 Core Competences 53
5.3. Pfizer Ltd. Taiwan Marquee Customers 55
5.4. Pfizer Inc. Strategic Alliances 58
5.5 Pfizer Inc. Exponential Returns 60
5.5.1 Revenues Analysis 60
5.5.2 EBIT, EBITDA and FCFF with the EV Relation Analysis 61
5.5.3 ROIC and WACC Analysis 63
5.5.4 Profitability Analysis 64
5.5.4.1 Return on Sales Analysis 64
5.5.4.2 Return on Investment Analysis 65
5.5.5 P/E Ratio Analysis 66
5.6 Pfizer Ltd. Taiwan Leadership and Management Team 67
5.7 Pfizer Inc. Board Members 69
5.8 Pfizer Inc. and Pfizer Ltd. Taiwan’s Key Success Factors 71
5.9 Recommendations 72
CHAPTER 6: CONCLUSIONS AND FURTHER RESEARCH 74
6.1 Conclusions 74
6.2 Further Research 75
REFERENCES 77
APPENDIX A: Pfizer Inc. Acquisitions in February 2000 – November 2012 81
APPENDIX B: Pfizer Inc. Alliances in February 2006 – April 2013 84
APPENDIX C: Pfizer Inc. Financial Statement and Analysis 87

Albright, K., 2010, ‘Can Pfizer Maintain Success In The U.S. Pharmaceutical Industry’, SlideShare Inc., April 22, viewed 28 November 2013 <http://www.slideshare.net/AileenMarshall/business-report-on-pfizer?from_search=15>
Bartlett, C.A. & Beamish, P.W., 2010, Transnational Management: Text, Cases, and Readings in Cross-Border Management, 6th edn, McGraw-Hill Higher Education, New York City, New York, United States of America
Blueprint Growth Institute, Inc., 2010, “Blueprint Companies”, Blueprint Growth Institute, Inc., viewed 28 November 2013 <http://www.blueprintgrowth.com/index.html>
Boldrin, M. & Levine, D.K., 2010, Against Intellectual Monopoly. Cambridge University Press, Cambridge, United Kingdom
Conroy, P., Chaudhuri, A. & Hukumchand, V., 2009, ‘Maximizing ROIC to Drive Growth in Consumer Products: Learning from the past, preparing for the future’, Delloite Development LLC, viewed 25 November 2013 <http://www.deloitte.com/view/en_us/us/d8dc8dfbf5f94210VgnVCM200000bb42f00aRCRD.htm >
Current Partnering, 2013a, ‘M&A deal activity’, Wildwood Ventures Ltd., viewed 26 November 2013 <http://www.currentpartnering.com/scorecard/deal-metrics/ma-deal-activity/>
Current Partnering, 2013b, ‘M&A scorecard’, Wildwood Ventures Ltd., viewed 26 November 2013 <http://www.currentpartnering.com/scorecard/ma/>
Current Partnering, 2013c, ‘Deal metrics’, Wildwood Ventures Ltd., viewed 26 November 2013 <http://www.currentpartnering.com/scorecard/deal-metrics/>
EFPIA, 2013, ‘The Pharmaceutical Industry in Figures’, EFPIA, viewed 26 November 2013 <http://www.efpia.eu/uploads/Figures_Key_Data_2013.pdf>
Gauntlett, C. & Rickwood, S., 2013, ‘The changing face of the top 10 pharmaceutical companies: The beginning of the end for innovative dominance’, IMS Health Inc., viewed 25 November 2013 <http://www.imshealth.com/deployedfiles/ims/Global/Asia%20Pacific/Content/Insights/Top10%20Pharma%20Companies%20WP%20final_for%20clients.pdf>
Google Finance, 2013, ‘Pfizer Inc.’, Google, viewed 3 December 2013 <http://www.google.com/finance?chdnp=0&chdd=0&chds=0&chdv=0&chvs=maximized&chdeh=0&chfdeh=0&chdet=1386077566301&chddm=3621051&chls=IntervalBasedLine&q=NYSE%3APFE&ntsp=0&fct=big&ei=I9udUqj-F86ZlQXYZg>
Harris, G., 2009, ‘Pfizer Pays $2.3 Billion to Settle Marketing Case’, The New York Times Company, September 2, viewed 29 November 2013 <http://www.nytimes.com/2009/09/03/business/03health.html>
Hitt, M.A., Ireland, R.D. & Hoskisson, R.E., 2011, The Management of Strategy: Concepts and Cases, International Edition, 9th edn, Cengage Learning, Stamford, Connecticut, United States of America
Hoyer, W.D. & MacInnis, D.J., 2001, Consumer Behaviour, 2nd edn, Houghton Mifflin Harcourt, Boston, Massachusetts, United States of America
Huang, Y.C., 2009, ‘Global Biomedical Industry Market Movement and Development Opportunity in Taiwan’, Department of Investment Services, MOEA, November 11, viewed 26 November 2013 <http://investtaiwan.org/eng/ind_news_display.jsp?newsid=3>
IMS Health Inc., 2013, ‘Top Line Market Data’, IMS Health Inc., viewed 28 November 2013 <http://www.imshealth.com/portal/site/ims/menuitem.5ad1c081663fdf9b41d84b903208c22a/?vgnextoid=fbc65890d33ee210VgnVCM10000071812ca2RCRD>
Investopedia, 2013, ‘Dictionary’, Investopedia US, A Division of ValueClick, Inc., viewed 29 November 2013 <http://www.investopedia.com/dictionary/>
Jeannet, J. P. & Hennessey, H. D., 1998, Global Marketing Strategies, 4th edn, Houghton Mifflin, Boston, Massachusetts, United States of America
McNiel Jr., D.G., 2011, ‘Nigerians Receive First Payments for Children Who Dies in 1996 Meningitis Drug Trial’, New York Times Company, August 11, viewed 30 November 2013 <http://www.nytimes.com/2011/08/12/world/africa/12nigeria.html?_r=0 >
NYSE EURONEXT, 2013, ‘Pfizer Inc.’, NYSE EURONEXT, viewed 28 November 2013 <http://www.nyse.com/about/listed/lcddata.html?ticker=pfe>
Pearson Education, Inc., 2010, ‘Market Segmentation and Strategic Targeting’, Prentice Hall, viewed 28 November 2013 <http://home.kku.ac.th/petmas/Segmenting%20and%20Targeting.pdf>
Pfizer Inc., 2010, Pfizer Inc., viewed 23 November 2013 <http://www.pfizer.com.tw/index.asp>
Pfizer Inc., 2013, Pfizer Inc., viewed 23 November 2013 <http://www.pfizer.com/>
PhRMA, 2013, ‘PhRMA: Profile 2013’. Pharmaceutical Research and Manufacturers of America, viewed 27 November 2013 <http://phrma.org/sites/default/files/pdf/PhRMA%20Profile%202013.pdf>
Skok, M., 2013, ‘4 Steps To Building A Compelling Value Proposition’, Forbes.com, June 14, viewed 28 November 2013 <http://www.forbes.com/sites/michaelskok/2013/06/14/4-steps-to-building-a-compelling-value-proposition/>
Stock Analysis on Net, 2013, ‘Pfizer Inc. (PFE)’, EBIT Financial Analyses Centre, viewed 31 November 2013 <http://www.stock-analysis-on.net/NYSE/Company/Pfizer-Inc>
The China Post, 2013, ‘Pfizer’s Hsinchu factory is biggest in Taiwan’, The China Post, February 27, viewed 28 November 2013 <http://www.chinapost.com.tw/taiwan/business/2010/02/27/246098/Pfizers-Hsinchu.htm>
Thomson, D.G., 2005, ‘The Blueprint Thesis: A Different Approach to Growth’, Blueprint Growth Institute, Inc., viewed 23 November 2013 <http://www.blueprintgrowth.com/business_growth_books/blueprint_to_a_billion/downloads/chapterone.pdf>
Thomson, D.G., 2006, Blueprint to A Billion: 7 Essentials to Achieve Exponential Growth, John Wiley & Sons, Inc., Hoboken, New Jersey, United States of America
Thomson, D.G., 2010, Mastering The 7 Essentials of High-Growth Companies, John Wiley & Sons, Inc., Hoboken, New Jersey, United States of America
Torres, E.M., 2010, ‘Financial Research: Johnson and Johnson and Pfizer Company, Risks, Stock Analysis’, SlideShare Inc., viewed 29 November 2013 <http://www.slideshare.net/Erick_Martinez/fiancial-research>
Wedel, M. & Kamakura, W., 2002, ‘Introduction to the Special Issue on Market Segmentation’, International Journal in Research in Marketing 19, Page 181-183, Elsevier Ltd., viewed 28 November 2013 <http://wak2.web.rice.edu/bio/My%20Reprints/IntroductiontothespecialissueonMarketSegmentation.pdf>